Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Dihexa: Evidence Summary
Evidence summary for Dihexa across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Dihexa overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Cognitive enhancement | Tier D | 0 | Preclinical only — potent HGF/c-Met activator in animal models of cognitive decline |
| Neuroprotection | Tier D | 0 | Animal studies show synaptogenesis promotion; no human trials conducted |